DFN-02 Open Label Safety Study in Patients With Acute Migraine

Phase 3

Completed

• Conditions: Acute Migraine
• Interventions: Drug: DFN-02

• Registration Number: NCT02279082
• Lead Sponsor: Dr. Reddy's Laboratories Limited

Brief Summary

A multi-center, open-label, safety study of DFN-02 for the Treatment of Acute Migraines

Detailed Description

Not available

Study Timeline

• Study Start: 2014-09
• Study First Submitted: 2014-10-23
• Study First Submitted QC: 2014-10-28
• Study First Posted: 2014-10-30
• Primary Completion: 2015-09
• Study Completion: 2016-03
• Results First Submitted: 2017-03-02
• Results First Submitted QC: 2017-07-27
• Results First Posted: 2017-08-28
• Status Verified: 2018-02
• Last Update Submitted: 2018-02-11
• Last Update Posted: 2018-03-09

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 167

Inclusion Criteria

1. Patients with a history of acute migraine (using International Classification of Headache Disorders [ICHD] criteria, second edition);

2. Patients who, in the opinion of the investigator, are willing and able to:

   • Return to the study site within 72 hours of the first use of study medication,
   • Record each migraine and each instance of the use of study medication and rescue medication in a patient diary for the duration of the study;

3. Patients who can use the nasal spray device correctly after instruction.

Read More

Exclusion Criteria

1. Patients on onabotulinumtoxinA (Botox®) or other botulinum toxin treatment; or history of receiving such treatment 180 days prior to screening;

2. Patients with a history of stroke or transient ischemic attack (TIA);

3. Patients with a history of migralepsy or a concurrent diagnosis of seizure disorder;

4. Patients who cannot differentiate between a migraine headache and a tension-type or cluster headache;

5. Patients with ischemic coronary artery disease (CAD; ie, angina pectoris, history of myocardial infarction or documented silent ischemia or coronary artery vasospasm, including Prinzmetal's angina);

6. Patients with Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders;

7. Patients with uncontrolled hypertension (screening systolic/diastolic blood pressure > 140/90 mmHg);

8. Patients with peripheral vascular disease or ischemic bowel disease;

9. Patients taking any medications or with illnesses likely to affect the physiology of the nasal mucosa (ie, patients with nasal septum surgery, chronic sinusitis, or chronic nasal rhinitis). (Note: Patients who have acute conditions such as acute sinusitis may be rescreened 14 days after resolution of acute sinusitis.);

10. Patients with any abnormal nasal physiology or pathology which, in the opinion of the investigator, would not allow the objectives of the study to be accomplished;

11. Patients with known intolerance to nasal sprays;

12. Patients with severe renal impairment (defined as serum creatinine > 2 mg/dL);

13. Patients with serum total bilirubin > 2.0 mg/dL;

14. Patients with serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), or alkaline phosphatase > 2.5 times the upper limit of normal (ULN);

15. Patients with a history of alcohol or substance abuse (including marijuana and medical marijuana) within 1 year that would compromise data collection;

16. Patients with a positive urine drug screen for illicit drugs or for prescription drugs not explained by stated concomitant medications. (Positive drug screen for marijuana is exclusionary.):

    1. Patients consuming opioids for the treatment of migraine or using opioids or barbiturates temporarily for a legitimate medical cause may participate as long as they do not meet the MOH criteria.
    2. Benzodiazepines are allowed if used for legitimate medical use.
    3. Chronic use of amphetamines to treat attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) and related disorders is allowed as long as the regimen has been stable for at least 3 months prior to screening and is expected to remain stable throughout the study.

    Note: For the above-mentioned conditions, the site must obtain medical monitor approval.

17. Patients with a history of or current neurological or psychiatric impairment, or cognitive dysfunction that, in the opinion of the investigator, would compromise data collection;

18. Patients who have received treatment with an investigational drug or device within 4 weeks of the screening visit or participated in a central nervous system clinical trial in the 3 months prior to screening;

19. Patients who test positive for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV) antibody serology testing.

20. Patients with any other medical condition that, in the judgment of the investigator or medical monitor, would confound the objectives of the study (eg, cancer history [except basal cell carcinoma], systemic lupus erythematosus)

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
DFN-02	DFN-02	DFN-02 to be taken during migraine attack

Primary Outcome Measures

Name	Time	Method
Number of Participants With Treatment Emergent Adverse Events	6 months

Trial Locations

Locations (24)

California Medical Clinic for Headache; 🇺🇸 Santa Monica, California, United States

Clinvest/A Division of Banyan Group, Inc.; 🇺🇸 Springfield, Missouri, United States

Arizona Research Center; 🇺🇸 Phoenix, Arizona, United States

Florida Clinical Research Center; 🇺🇸 Bradenton, Florida, United States

Future Search Trials of Dallas, LP; 🇺🇸 Dallas, Texas, United States

Collaborative Neuroscience Network, LLC; 🇺🇸 Long Beach, California, United States

Dent Neurologic Institute; 🇺🇸 Amherst, New York, United States

Michigan Head Pain & Neurological Institute; 🇺🇸 Ann Arbor, Michigan, United States

Albuquerque Clinical Trials, Inc.; 🇺🇸 Albuquerque, New Mexico, United States

Northern California Clinical Research Center; 🇺🇸 Redding, California, United States

Neurology Clinical Research, Inc; 🇺🇸 Sunrise, Florida, United States

Stanford University Medical Center; 🇺🇸 Stanford, California, United States

Carman Research; 🇺🇸 Smyrna, Georgia, United States

Associated Neurologists of Southern CT, P.C.; 🇺🇸 Fairfield, Connecticut, United States

FutureSearch Trials of Neurology, LP; 🇺🇸 Austin, Texas, United States

Upstate Clinical Research Associates LLC; 🇺🇸 Williamsville, New York, United States

Protenium Clinical Research, LLC; 🇺🇸 Bedford, Texas, United States

Breakthrough Clinical Trials; 🇺🇸 San Bernardino, California, United States

Florida Clinical Research Center, LLC; 🇺🇸 Maitland, Florida, United States

San Francisco Clinical Research Center; 🇺🇸 San Francisco, California, United States

Community Research; 🇺🇸 Cincinnati, Ohio, United States

Novex Clinical Research; 🇺🇸 New Bedford, Massachusetts, United States

MedVadis Research Corporation; 🇺🇸 Watertown, Massachusetts, United States

Thomas Jefferson University; 🇺🇸 Philadelphia, Pennsylvania, United States